Synthesis of Omphalotin A and familiar Secundary Metabolites
Patent 17024/TUB

This Invention enables the Synthesis of Omphalotin A and modified secundary metabolites for the development of novel antibiotics.

Benefits
  1. Higher yield and purity
  2. Controllable fed-batch-cultivation
  3. Synthesis of natural and artificial Omphalotins
  4. Usa of fungal expression systems
Possible Applications

Pharma industry, plant protection products, biological research

Background

The production of new antibiotics based on cyclodepsipeptides (CDPs) is known to be problematic on an industrial scale. Their synthesis can be optimized by using fungal expression systems. Omphalotin A, a product of particular interest here, shows strong and selective activity against plant pathogenic nematodes. The fungal, ribosomally synthesized and posttranslationally modified peptide (RiPP) offers the possibility of further investigation of this hitherto unexplored field. In addition, Omphalotin A shows the peculiarity of N-methylations in the peptide backbone, a structural property previously only known for non-ribosomal peptides.

Technical Description

The invention presented here involves the synthesis of Omphalotin A and its modified secondary metabolites in fungal host organisms (Genera Aspergillus, Penicillium, and Yeast). The necessary enzymes were identified and modified by the introduction of altered gene sequences (synthetic or by PCR). This allows the selective production of either natural or modified Omphalotins. The advantages of this method are the possibility of fed-batch cultivation in a bioreactor using a genetically modified host organism and optimized metabolism independent expression. This enables satisfactory metabolite yields with high purity, including the production of linear N-methylated peptides.

Contact Us

Ina Krüger

License Manager

+49 (0)30 314-75916
ina.krueger@tu-berlin.de

Technology Readiness Level
TRL 4

Small scale prototype

Property Rights

pending: PCT

Patent Holder

Technische Universität Berlin

Possible Cooperation
  • R&D Cooperation
  • Patent Purchase
  • Licensing